GURUFOCUS.COM » STOCK LIST » Latin America » Brazil » BSP » Biogen Inc (BSP:BIIB34) » Definitions » Cash Receipts from Operating Activities
Switch to:

Biogen (BSP:BIIB34) Cash Receipts from Operating Activities


View and export this data going back to 2016. Start your Free Trial

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Biogen (BSP:BIIB34) Business Description

Biogen logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Cash Receipts from Operating Activities
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.